Diabetes Drug
GLP-1 agonists have transformed diabetes care. What's next in the pipeline?
A (Endocrinologist): The dual agonists (tirzepatide - GLP-1/GIP) and triple agonists (retatrutide - GLP-1/GIP/glucagon) are even more potent. Tirzepatide achieves A1c reductions of 2.0-2.5% and weight loss of 15-20% in clinical trials. Retatrutide showed 24% weight loss at 48 weeks in Phase 2. Side effects (nausea, vomiting, gastroparesis) are dose-limiting.
B (Pharmacist - Clinical): The shortage crisis is real and ethically fraught. Off-label prescribing for cosmetic weight loss to the "worried well" has created scarcity for patients with type 2 diabetes who need these drugs for glucose control. We need tiered access, dedicated manufacturing lines for diabetes indications, or prior authorization requirements.
C (Payer/Insurer): At $1,000+ per month per patient, these drugs will bankrupt Medicare and Medicaid. The Congressional Budget Office projects that if just 10% of obese adults take GLP-1s, it would cost $350 billion over 10 years. We're requiring step therapy (metformin → sulfonylureas → SGLT2 → GLP-1). Drug companies need to compete on price.
D (Patient with T2DM): I suffered on metformin for 10 years with disabling diarrhea. Ozempic gave me my life back—A1c from 9.2 to 6.1, lost 45 lbs, no side effects. Now my insurance is threatening to drop coverage because I'm "not diabetic enough" since my A1c improved. That's perverse. Don't punish patients for responding to treatment.